Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial
Abstract Background Despite robust weight loss and cardiometabolic benefit, lean mass loss following sleeve gastrectomy (SG) confers health risk. Bisphosphonates are a potential therapeutic agent for lean mass maintenance. Thus, our objective was to explore the effect of 6 months of risedronate (vs....
Main Authors: | Laura E. Flores, Kristen M. Beavers, Daniel P. Beavers, Katelyn A. Greene, Diana A. Madrid, Ryan M. Miller, Jamy D. Ard, Laura D. Bilek, Ashley A. Weaver |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | JCSM Rapid Communications |
Subjects: | |
Online Access: | https://doi.org/10.1002/rco2.72 |
Similar Items
-
Strategies to reduce the onset of sleeve gastrectomy associated bone loss (STRONG BONES): Trial design and methods
by: Joshua R. Stapleton, et al.
Published: (2023-08-01) -
The Art of Sleeve Gastrectomy
by: Shahed Tish, et al.
Published: (2024-03-01) -
Effects of antiresorptive agents on body composition: a case-control retrospective study
by: Suhel Gabriele Al Khayyat, et al.
Published: (2023-01-01) -
Revisional Surgeries of Laparoscopic Sleeve Gastrectomy
by: Li S, et al.
Published: (2021-02-01) -
THE ROUTINE USE OF THE METHYLENE BLUE TEST IN SLEEVE GASTRECTOMY: WHY NOT?
by: Álvaro A. B. FERRAZ, et al.
Published: (2022-01-01)